Cabometyx (cabozantinib) offers efficacy benefits in combination with Bristol Myers Squibb’s Opdivo (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma, regardless of prior nephrectomy status, according to data from a post-hoc exploratory analysis of the phase III CheckMate -9ER pivotal trial.
The Leukemia & Lymphoma Society published a study showing that more than one in two patients with B-cell blood cancers produced antibodies to a third dose of COVID-19 vaccine, despite having no detectable antibodies after the first two doses.
Researchers at MD Anderson Cancer Center demonstrated that stereotactic ablative radiotherapy was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer and generated minimal side effects.
Keck School of Medicine of USC researchers found that children born with a genetic predisposition to produce more lymphocytes, particularly in relation to other types of white blood cells, are at a higher risk of developing acute lymphoblastic leukemia.
Cedars-Sinai Cancer and Tempus, an artificial intelligence and precision medicine company, are using big data and AI to design personalized cancer treatment options, creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease.
As adolescents return to school, public health experts caution parents to pay close attention to signs of tobacco use among teens.
In a study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.
An advanced type of radiation therapy at Miami Cancer Institute, part of Baptist Health South Florida, is offering patients ablative MR-guided radiation therapy, which may prolong survival for patients with inoperable pancreatic cancer.
Research from a large international effort shows that 20% of children with cancer who are infected with SARS-CoV-2 develop severe infections.
The National Comprehensive Cancer Network has updated the NCCN: Cancer and COVID-19 Vaccination guidance with information on the third mRNA COVID-19 vaccine.
